Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
The Pharmaceutical Research and Manufacturers of America (PhRMA) raised alarm over Tokyo’s response to the US most-favored-nation (MFN) pricing policy on April 17, warning that failure to act could make drug launches in Japan less commercially viable. Speaking at a…
To read the full story
Related Article
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
ORGANIZATION
- PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
- 60% of EFPIA Firms Could Cut Japan Trial Investments without Policy Reform
October 2, 2026
- JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
- Generic Use Rate Hits Record 90.4% in April-June: JGA
September 30, 2026
- JaDHA Calls for Digital Health Seat in Chuikyo Reform
September 28, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…